The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years (Q43818994)

27 November 2017

The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years (English)

1 reference

27 November 2017

1

Robert C Gallo

1 reference

PubMed ID

16310557

27 November 2017

language of work or name

English

0 references

publication date

28 September 2005

1 reference

27 November 2017

1 reference

27 November 2017

366

1 reference

27 November 2017

9500

1 reference

27 November 2017

1894-1898

1 reference

Live attenuated HIV vaccines: pitfalls and prospects

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Overview of the needs and realities for developing new and improved vaccines in the 21st century

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Genomic diversity of human T-lymphotropic virus type III (HTLV-III).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Biologically diverse molecular variants within a single HIV-1 isolate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Public health. AIDS vaccine trial produces disappointment and confusion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Cellular uptake of the tat protein from human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Viral evolution and challenges in the development of HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Oral presentation abstracts from the 13th International Symposium on HIV and Emerging Infectious Diseases (ISHEID). June 3-5, 2004. Toulon, France

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Public health. A sound rationale needed for phase III HIV-1 vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Policy rebuttal. HIV vaccine trial justified.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Support for the RV144 HIV vaccine trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Up-regulation of beta-chemokines and down-modulation of CCR5 co-receptors inhibit simian immunodeficiency virus transmission in non-human primates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

HIV-1 entry inhibitor entrances

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

HIV vaccine design and the neutralizing antibody problem

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Diversity considerations in HIV-1 vaccine selection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967395-3

7 January 2021

10.1016/S0140-6736(05)67395-3

Identifiers

DOI

1 reference

27 November 2017

1 reference

PubMed ID

16310557